| Literature DB >> 30155258 |
Filipa Mousinho1, Paula Sousa E Santos1, Ana P Azevedo2,3,4, José Manuel Pereira5, Raquel Lemos6, Sónia Matos7, João Faro Viana2,5, Fernando Lima1.
Abstract
Patients with a Philadelphia chromosome-negative myeloproliferative neoplasm may develop a lymphoproliferative disorder; however, the clinical and molecular determinants and the chronological onset of the two events remain unknown. We herein report the case of a 64-year-old man with concomitant diagnosis of high-risk essential thrombocythemia with evidence of a thrombotic event and high-count monoclonal B-cell lymphocytosis (high-count MBL). The patient harbored a JAK2V617F mutation and one of the most common genetic alterations found in chronic lymphocytic leukemia (CLL) (del 13q), which may represent a sign of disease progression. He was initiated on cytoreductive therapy with hydroxyurea 500 mg 3 times per week and hypocoagulation treatment, and is currently under regular surveillance of MBL without CLL criteria.Entities:
Keywords: JAK2V617F mutation; del(13q); essential thrombocythemia; lymphoproliferative neoplasms; monoclonal B cell lymphocytosis; myeloproliferative neoplasms
Year: 2018 PMID: 30155258 PMCID: PMC6109675 DOI: 10.3892/mco.2018.1682
Source DB: PubMed Journal: Mol Clin Oncol ISSN: 2049-9450